Navigation Links
Cleveland Clinic research finds blood pressure drug tends to slow coronary disease
Date:9/8/2013

Tuesday, Sept. 3, 2013, Cleveland: Patients with clogged and hardened arteries who already have their blood pressure under control may benefit from an additional blood pressure-lowering medication, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

The researchers found that the renin-inhibitor aliskiren tended to slow coronary disease progression and reduced the risk of death, stroke and heart attack in these patients by about 50 percent, compared to placebo, suggesting that patients with prehypertension may benefit from blood pressure lowering drugs.

The results of the AQUARIUS (Aliskerin Quantitative Atherosclerosis Regression Intravascular Ultrasound Study) trial were presented today at the European Society of Cardiology Congress 2013 and published simultaneously in the Journal of the American Medical Association.

Aliskiren affects the body's renin-angiotensin-aldosterone system (RAAS), a hormone system that regulates blood pressure and has been shown in prior studies to play an important role in the development of atherosclerosis, or the hardening or clogging of the arteries. As a renin inhibitor, aliskiren partially blocks renin from triggering the RAAS process and is approved to treat hypertension to optimal guidelines of 140/90 mmHg, or the high end of the prehypertensive range.

AQUARIUS, a prospective, randomized, multicenter, double-blind clinical trial, was designed to test whether renin inhibition could slow or reverse the progression of coronary artery disease in patients who have their blood pressure under control in the prehypertensive range. The study also looked at whether these patients would benefit from additional blood pressure-lowering medication, even though their blood pressure was considered to be under control.

A team of researchers led by Stephen J. Nicholls, M.D., Ph.D., senior consultant to Cleveland Clinic's C5Research and Professor of Cardiology and Deputy Director at the South Australian Health & Medical Research Institute (SAHMRI) in Adelaide, Australia, used intravascular ultrasonography (IVUS) to assess the degree of coronary disease progression in 458 patients at baseline and after 104 weeks of treatment with aliskiren or placebo. IVUS is a medical imaging technology in which a small ultrasound probe is inserted via a catheter into an artery, allowing physicians to examine the inside of arteries via sonogram.

"We found that aliskiren had a moderate effect on reducing blood pressure, substantially reduced renin activity, and produced a compensatory increase in renin concentration in the blood plasma," Dr. Nicholls said. "We also saw a bit of a trend toward regression in atherosclerosis. But our primary endpoint a decrease in the volume of disease in the artery did not meet statistical significance."

Although not a primary endpoint, the researchers did identify a decrease in major cardiovascular events including sudden death, stroke, and heart attack in patients on aliskiren. The data indicate that patients with heart disease and blood pressure in the prehypertensive range may benefit from more aggressive treatment of their blood pressure to get it lower than current guidelines suggest.

"We have to be cautious interpreting our results on cardiovascular events because this trial was not formally designed to look at these outcomes," said Steven Nissen, M.D., Chairman of the AQUARIUS trial executive committee and Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic. "However, the data indicate that renin inhibition is safe in patients who have coronary artery disease and have their blood pressure under control, and it may have some beneficial cardiovascular effects."


'/>"/>

Contact: Wyatt DuBois
duboisw@ccf.org
216-445-9946
Cleveland Clinic
Source:Eurekalert

Related medicine news :

1. Cleveland Clinic selected to participate in National MDS Clinical Research Consortium
2. Cleveland Clinic researchers discover molecule that may prevent atherosclerosis
3. Cleveland Clinic Florida receives approval for transplant programs at Weston Facilities
4. Cleveland Clinic researchers investigating potential drug for treatment of Alzheimers disease
5. Cleveland Clinic study shows vitamin E may decrease cancer risk in Cowden syndrome patients
6. University Hospitals & Philips Healthcare to showcase imaging technology at Cleveland Medical Mart
7. Cleveland Clinic researcher identifies 2 new genetic mutations associated with Cowden syndrome
8. Redskins Quarterback & Lynx Shreds Athlete Kirk Cousins will Start Today vs. Cleveland Browns for Injured RG3
9. Cleveland Clinic researcher receives grant to fund autism research
10. Cleveland Clinic study shows bariatric surgery restores pancreatic function by targeting belly fat
11. Vein Expert in Winston-Salem, NC Participates in Elite Cleveland Clinic Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: